Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- FMC -13.9% (guidance), HOPE -3.4%
Other news:
- RVMD -35.6% (presents promising clinical activity and safety data from Phase 1/1b Trial of RMC-6236)
- EPIX -3.3% (Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress)
- CVX -2.7% (Hess to be acquired by Chevron for $171 per share)
- VTRS -2.6% (President to retires April 1, 2024; also downgraded to Underperform from Neutral at BofA Securities)
- BLNK -2.2% (files universal shelf registration statement for up to $400 million of common stock, preferred stock, debt securities and warrants)
- EXAS -1.2% (advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress; reports Next-Generation Cologuard Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection)
- TSLA -1.2% (disloses in 10Q filing that its expects its capital expenditures to exceed $9.00 billion in 2023 and be between $7.00 to $9.00 billion in each of the following two fiscal years)
- TLT -0.9% (US 10-yr yiled over 5%)
Analyst comments:
- AA -3.1% (downgraded to Neutral from Buy at BofA Securities)
- FANG -1.5% (downgraded to Neutral from Buy at Citigroup)
- EOG -1.5% (downgraded to Neutral from Buy at Citigroup)
- ELS -1% (downgraded to Neutral from Buy at BofA Securities)